GEHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GE Healthcare Technologies Inc (GEHC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as FDA clearance for advanced imaging technology and a solid revenue growth trend, the recent financial performance shows declining net income, EPS, and gross margin. Additionally, hedge funds are selling, and technical indicators suggest a bearish trend. With no strong trading signals from AI Stock Picker or SwingMax, it is advisable to hold off on buying until the stock shows stronger upward momentum or improved financial metrics.
The MACD is positive and expanding, indicating some bullish momentum. However, RSI is neutral at 45.584, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 71.36, with resistance at 73.228 and support at 69.492, suggesting limited upside in the short term.
FDA clearance for Photonova Spectra, an advanced imaging technology.
Participation in the COMPASS initiative to enhance cardiac health for cancer patients.
Revenue growth of 7.13% YoY in Q4 2025.
Hedge funds are selling, with a 129.92% increase in selling activity last quarter.
Declining net income (-18.31% YoY), EPS (-17.83% YoY), and gross margin (-7.22% YoY) in Q4
Bearish moving averages and limited short-term upside based on technical indicators.
In Q4 2025, revenue increased by 7.13% YoY to $5.698 billion. However, net income dropped by 18.31% YoY to $589 million, EPS declined by 17.83% YoY to 1.29, and gross margin fell by 7.22% YoY to 39.68%.
Analyst ratings are mixed. Citi recently lowered its price target to $84 with a Neutral rating, while Argus raised its target to $95 with a Buy rating. Other firms like Barclays and Morgan Stanley maintain Equal Weight ratings with modest price target increases. The consensus reflects cautious optimism but no strong bullish sentiment.
